Outlook Therapeutics Share Price Today

Outlook Therapeutics appoints Greg DiPasquale as chief commercial officer

Greg DiPasquale appointed Chief Commercial Officer to lead US commercial functions. Launch of LYTENAVA for wet AMD targeted in United States before end of 2026. DiPasquale brings 30 years experience including prior retina product launches. LYTENAVA is the only FDA-approved ophthalmic bevacizumab formulation in US.

Outlook Therapeutics appoints Kevin Lundquist as CFO ahead of LYTENAVA launch

Outlook Therapeutics appoints Kevin Lundquist as CFO effective September 1, 2026. Lundquist brings 20+ years of experience, including leading CapsoVision through its 2025 IPO. He receives an inducement grant of 500,000 stock options vesting over four years. Lawrence Kenyon steps down as CFO but remains as non-executive employee until September 30. Appointment supports U.S. commercial launch of FDA-approved LYTENAVA for wet AMD.

Outlook Therapeutics Q3 FY26 loss narrows; FDA approves Lytenava

Outlook Therapeutics reported a Q3 FY26 adjusted net loss of $10.9 million, down from $15.8 million in the prior year, driven by reduced R&D and SG&A expenses. Revenue fell to $9,000 from $1.5 million. The company secured FDA approval for Lytenava, targeting $500 million in peak US sales by 2030, and completed a $51.1 million capital raise to fund the commercial launch.

Outlook Therapeutics prices $55M stock and warrant offering

Outlook Therapeutics Inc (NASDAQ: OTLK) has priced a $55.0 million underwritten public offering of 55,555,556 shares of common stock and accompanying warrants at a combined price of $0.99 per unit. Piper Sandler and BTIG serve as joint bookrunning managers, with Brookline Capital Markets as lead manager. The company intends to use the net proceeds to support the US commercial launch of LYTENAVA (bevacizumab-vikg) for retinal diseases and for working capital and general corporate purposes. The offering includes an over-allotment option for up to 8,333,333 additional shares and warrants.

Outlook Therapeutics files prospectus for 17.258M share offering

Outlook Therapeutics filed a prospectus for the sale of 17.258M common shares by selling stockholders. The company will not receive any proceeds from this offering.

Outlook Therapeutics secures FDA acceptance for wet AMD drug review

Outlook Therapeutics Inc. announced that the FDA accepted the resubmitted BLA for ONS-5010/LYTENAVA for wet AMD treatment. The filing was classified as a Class 1 review with a PDUFA target action date of July 29, 2026. The company is preparing for commercialization, aiming to offer the first FDA-approved ophthalmic formulation of bevacizumab.